tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

EXEL Stock Latest News

Optimistic Buy Rating for Exelixis Amid Promising Phase III Trial Results for Zanzalintinib
RatingsOptimistic Buy Rating for Exelixis Amid Promising Phase III Trial Results for Zanzalintinib
9h ago
EXEL
Novo Nordisk, Grab, Vistra, Exelixis, Dropbox: Trending by Analysts
PremiumWeekend Updates
Novo Nordisk, Grab, Vistra, Exelixis, Dropbox: Trending by Analysts
11d ago
DBX
NVO
Netflix upgraded, Five Below initiated: Wall Street’s top analyst calls
PremiumThe Fly
Netflix upgraded, Five Below initiated: Wall Street’s top analyst calls
14d ago
Z
KR
Exelixis: Strong Growth Potential with Promising Zanzalintinib Outlook and Attractive Investment Opportunity
PremiumRatings
Exelixis: Strong Growth Potential with Promising Zanzalintinib Outlook and Attractive Investment Opportunity
14d ago
EXEL
Exelixis price target raised to $50 from $46 at Morgan Stanley
PremiumThe Fly
Exelixis price target raised to $50 from $46 at Morgan Stanley
14d ago
EXEL
Exelixis initiated with a Buy at Goldman Sachs
PremiumThe FlyExelixis initiated with a Buy at Goldman Sachs
14d ago
EXEL
Exelixis assumed with an Equal Weight at Barclays
Premium
The Fly
Exelixis assumed with an Equal Weight at Barclays
14d ago
EXEL
Exelixis initiated with an Equal Weight at Barclays
Premium
The Fly
Exelixis initiated with an Equal Weight at Barclays
14d ago
EXEL
Exelixis Advances Phase 1 Study of XL309 for Advanced Solid Tumors
PremiumCompany Announcements
Exelixis Advances Phase 1 Study of XL309 for Advanced Solid Tumors
24d ago
EXEL
Exelixis Advances in Neuroendocrine Tumor Treatment with New Clinical Trial
PremiumCompany Announcements
Exelixis Advances in Neuroendocrine Tumor Treatment with New Clinical Trial
24d ago
EXEL
Exelixis’s Promising Growth Potential and Strategic Expansion Justify Buy Rating
PremiumRatings
Exelixis’s Promising Growth Potential and Strategic Expansion Justify Buy Rating
26d ago
EXEL
Exelixis Announces New Executive VP for R&D
PremiumCompany Announcements
Exelixis Announces New Executive VP for R&D
1M ago
8K
EXEL
Exelixis’s Promising Study on XB371: A New Hope for Solid Tumors
PremiumCompany AnnouncementsExelixis’s Promising Study on XB371: A New Hope for Solid Tumors
1M ago
EXEL
Exelixis and Novartis: Key Updates from the Pan Tumor Rollover Study
Premium
Company Announcements
Exelixis and Novartis: Key Updates from the Pan Tumor Rollover Study
1M ago
EXEL
Exelixis’s Promising Study on Renal Cell Carcinoma: A Potential Game Changer?
Premium
Company Announcements
Exelixis’s Promising Study on Renal Cell Carcinoma: A Potential Game Changer?
1M ago
EXEL
Exelixis’s Innovative RCC Study: A Potential Game-Changer?
PremiumCompany Announcements
Exelixis’s Innovative RCC Study: A Potential Game-Changer?
1M ago
EXEL
Exelixis’s Promising Study on Renal Cell Carcinoma: Key Updates for Investors
PremiumCompany Announcements
Exelixis’s Promising Study on Renal Cell Carcinoma: Key Updates for Investors
1M ago
EXEL
Pan-Tumor Rollover Study: A New Horizon in Long-term Cancer Treatment
PremiumCompany Announcements
Pan-Tumor Rollover Study: A New Horizon in Long-term Cancer Treatment
2M ago
BMY
NVS
Exelixis price target lowered to $46 from $53 at H.C. Wainwright
PremiumThe Fly
Exelixis price target lowered to $46 from $53 at H.C. Wainwright
2M ago
EXEL
Exelixis and Merck’s Promising Study on Renal Cell Carcinoma Treatment
PremiumCompany AnnouncementsExelixis and Merck’s Promising Study on Renal Cell Carcinoma Treatment
2M ago
EXEL
Pan-Tumor Rollover Study: A New Horizon in Cancer Treatment
Premium
Company Announcements
Pan-Tumor Rollover Study: A New Horizon in Cancer Treatment
2M ago
BMY
NVS
Exelixis price target lowered to $38 from $43 at UBS
Premium
The Fly
Exelixis price target lowered to $38 from $43 at UBS
2M ago
EXEL

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >